Contact: Alexander Shtifman
Phone: 617-713-8989

On January 15th 2010, Dr. Leslie E. Silberstein of the Center for Human Cell Therapy Boston (CHCT) at the Immune Disease Institute was awarded a Production Assistance for Cellular Therapies contract (PACT) by the National Institutes of Health. CHCT Boston was created in 2004 to promote the development of novel cellular therapies. CHCT Boston is led by Dr. Leslie Silberstein (Joint Program in Transfusion Medicine at Children's Hospital Boston, Brigham and Women's Hospital, and Dana Farber Cancer Institute) and Dr. Jerome Ritz (Dana Farber Cancer Institute), who serves as co-director.

The intent of this competitive award is to advance cellular therapy research in broad areas, including immunotherapy for cancer/infectious disease and stem cell therapy for congenital and acquired disorders. The 5-year program, funded in the amount of $14.5 million will be a cross-institutional effort including all major Harvard Medical School affiliated institutions as well as the Harvard Stem Cell Institute.

CHCT Boston will join 4 cell processing facilities nationwide. As a member of the PACT Group, CHCT Boston, comprised of the Translational Laboratory (Trans Lab) and the Connell O'Reilly Cell Manipulation Core Facility (CMCF) of the Dana Farber Cancer Institute, will partner with the PACT Steering Committee to identify basic laboratory investigators who have developed successful cell-based therapies in pre-clinical model systems and support the transition of these new approaches to the stage of clinical evaluation in patients. In addition to supporting investigators in translational research, the PACT Group also will offer educational resources for the cell therapy research community.

PACT will begin accepting new applications starting March 1st, 2010. For additional information on PACT application guidelines please visit or contact Darah Tappitake, Administrative Manager, CHCT, at


Darah Tappitake
(617) 919-2390